Seeking Alpha

martin640b

martin640b
Send Message
View as an RSS Feed
View martin640b's Comments BY TICKER:
Latest  |  Highest rated
  • Recent Moves By Pfizer Management: No Big Deal Or Telegraphing A Sell-Off? [View article]
    Just the opposite. This doesn't seem like the type of person to promote and after 3 years spin off as the new CEO of a stand-alone business. They may sell/spin off part or all of the generics, but I would think they keep the 2 innovative units with Geno becoming the next CEO. John is the type for being a CEO of a spun unit. Amy was a complete mystery as to why she was in an operating role. Perhaps they figured out the obvious - she had no clue as to what to do. Just listen to the quarterly calls - Geno and John are obvious CEOs in the making, she is not.
    Dec 17, 2013. 05:46 PM | 1 Like Like |Link to Comment
  • Onyx Pharmaceuticals: 3 Reasons Why Pfizer Won't Buy [View article]
    A PFE + Bayer bid would be about Bayer putting in 1B for the 2 drugs it co-markets with PFE putting up 9B to get Pablo outright plus the other new drug.
    Jul 14, 2013. 10:26 PM | Likes Like |Link to Comment
  • Merck's $5.7 Billion Diabetes Franchise Is Vulnerable [View article]
    Part of the reason behind the PFE partnership is to create a broader combo drug to Janumet to attempt to use minimum dosage levels of each component so not to hammer any one mechanism and get these side effect issues.
    Jul 12, 2013. 02:39 PM | Likes Like |Link to Comment
  • Is Amgen's $120 Offer For Onyx Too Low? - Part 3 [View article]
    And that is the path a PFE would take. Add in some money from Bayer (they would have to, at least, divest Nexavar) and you could see them go in at $140. I doubt anyone could knock off a PFE+Bayer bid, the big question is will they even bid (really bid, not just drive up the price to inflict pain on Amgen).
    Jul 3, 2013. 01:50 AM | Likes Like |Link to Comment
  • Amgen's (AMGN) blockbuster Enbrel drug for treating rheumatoid arthritis, which generated sales of $4.23B last year, is no more effective than a combination of three generic treatments, a study shows. While a regimen that includes Enbrel costs $25,000 a year per patient, the "triple therapy" costs just $1,000. The research didn't examine similar drugs from AbbVie (ABBV) or Johnson & Johnson (JNJ), although many doctors consider them to be equivalent to Enbrel. Despite the study, researchers feel that the branded treatments might be too well ensconced to be quickly replaced. [View news story]
    Research sponsored by an agency that only allows generics. I am shocked, absolutely shocked, that they have magically found a generic equivalent (really non-inferior) for a class of drugs that the government has targeted as enemy #1 for their budget. And published by the former haunt of Marcia Angell. Now there is a nice combination of biased agendas that, if subjected to a double-blind, would certainly come up inferior. Even better news: Dr. O'Dell has a 4 drug combo of 50 year old cancer meds that showed superiority to Avastin in a mid trial peek at the data and a 17 drug generic combo that cures the common cold, but is only in Phase II, so you'll have to wait on that one.
    Jun 12, 2013. 10:41 PM | Likes Like |Link to Comment
  • Pfizer's Potential Upcoming Dividend Increase [View article]
    It is better to use adjusted earnings, in which case the the payout ratio is about 40% which is their stated target. Based on adj. earnings growth for 2013 and the 40% target, $0.96 ($0.24 quarterly) is the likely number for the 2013. Keep in mind the stock buybacks that increase the dividend per share even with a constant dollar amount allocated to dividends - so you don't need just organic growth to support dividend growth.
    Nov 14, 2012. 09:35 AM | Likes Like |Link to Comment
  • Pfizer Divestitures Part 3: Sale of Capsugel to KKR Is Positive [View article]
    PFE needs to keep pipeline aligned with pipeline and product aligned with product. If it needs more pipe from a failure or a missing portfolio component, then it needs to use money (yes it is fungible) from the R&D budget perspective - buying a Seattle Genetics or Medigene (for Endo-Tag) - are really R&D actions. If a product goes LOE, then it needs to buy product (not an experimental pipe from a small biotech) or if it sells an asset it needs to buy an asset, in this case PFE stock which as you rightly point out is very inexpensive (I prefer that over cheap). Nutritionals next…
    Apr 5, 2011. 10:30 AM | Likes Like |Link to Comment
  • Pfizer Divestitures Part 3: Sale of Capsugel to KKR Is Positive [View article]
    PFE needs to keep pipeline aligned with pipeline and product aligned with product. If it needs more pipe from a failure or a missing portfolio component, then it needs to use money (yes it is fungible) from the R&D budget perspective - buying a Seattle Genetics or Medigene (for Endo-Tag) - are really R&D actions. If a product goes LOE, then it needs to buy product (not an experimental pipe from a small biotech) or if it sells an asset it needs to buy an asset, in this case PFE stock which is very inexpensive (I prefer that over cheap). Nutritionals next…
    Apr 5, 2011. 10:18 AM | Likes Like |Link to Comment
  • Pfizer Divestitures Part 1: Greater Than the Sum of Its Parts [View article]
    All the talk of a massive breakup was for Wall Street consumption - hence why Read gave it to Anderson. The reality will be somewhere in between. Steere, Lorch, and Read will continue to be one in the same. From the Warner-Lambert purchase press release, the 3 core focuses are human RX, OTC, and Animal Health. They will get rid of Capsugel and Nutritionals, but keep the rest. There is no point in doing Emerging Markets and not feed Established Products the same drugs to get lower costs. A much better idea is to get rid of the manufacturing by spinning it out with CentreSource (why is PFE a contract manufacturer?), keep 40% ownership to force lower costs yet not have to consolidate the financials.
    Mar 31, 2011. 02:20 PM | Likes Like |Link to Comment
  • Pfizer Divestitures Part 2: Who's Buying? [View article]
    All the talk of a massive breakup was for Wall Street consumption - hence why Read gave it Anderson. The reality will be somewhere in between. Steere, Lorch, and Read will continue to be one in the same. From the Warner-Lambert purchase press release, the 3 core focuses are human RX, OTC, and Animal Health. They will get rid of Capsugel and Nutritionals, but keep the rest. There is no point in doing Emerging Markets and not feed Established Products the same drugs to get lower costs. A much better idea is to get rid of the manufacturing by spinning it out with CentreSource (why is PFE a contract manufacturer?), keep 40% ownership to force lower costs yet not have to consolidate the financials.
    Mar 31, 2011. 02:14 PM | Likes Like |Link to Comment
COMMENTS STATS
11 Comments
1 Like